Nanjing IASO Biotherapeutics announced that it will receive investment in a equity round of funding from new investor Innovent Biologics, Inc. for 18% stake on July 5, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.8 HKD | -4.67% | +2.72% | -11.58% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.58% | 826.31Cr | |
+3.11% | 9.77TCr | |
+4.21% | 4.14TCr | |
-11.86% | 3.29TCr | |
+80.99% | 2.93TCr | |
-14.25% | 1.55TCr | |
-7.36% | 1.29TCr | |
-13.08% | 1.15TCr | |
+176.65% | 1.07TCr | |
-57.36% | 897.35Cr |
- Stock Market
- Equities
- 1801 Stock
- News Innovent Biologics, Inc.
- Nanjing IASO Biotherapeutics announced that it expects to receive funding from Innovent Biologics, Inc.